FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashing	ton. D	).C. 2	20549

STATEMENT	OF	<b>CHANGES</b>	IN	BENEFICIAL	<b>OWNERSHII</b>
STATEMENT	OF	CHANGES	IN	BENEFICIAL	OWNERSHII

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Polymeropoulos Mihael Hristos					2. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [ VNDA ]									able)	Perso	10% Ov	vner		
(Last) 2200 PEI SUITE 3	NNSYLVA	First) NIA AVENUE	(Middle)		02/	3. Date of Earliest Transaction (Month/Day/Year) 02/16/2023						Pro	X Officer (give title X Other (specify below)  President and CEO / Chairman of the Board				e Board		
(Street) WASHIN	NGTON E		20037 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc Line)							
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			2. Transa Date (Month/D		Execution Date,		Code (Instr.					Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
						Code	v	Amount (A) or (D)		(A) or (D)	Price	Transacti	Transaction(s) (Instr. 3 and 4)			(111311. 4)			
Common Stock 02/1			02/16	5/202	5/2023		A		115,000 <sup>(1)</sup> A		\$0.00	1,521,866			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	ansaction ode (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	Owners Form: Direct (I or Indire (I) (Instr	Ownership	Beneficial Ownership (Instr. 4)
				Co	ode \	v	(A)		Date Exercisab		Expiration Date	Title	o N	mount r umber f Shares		Transacti (Instr. 4)	on(s)		
Stock Option (Right to Buy)	\$7.05	02/16/2023			A		275,000		(2)	C	)2/15/2033	Comi		75,000	\$0.00	275,00	00	D	

## **Explanation of Responses:**

- 1. Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2024, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- 2. The option vests with respect to 25% of the underlying shares on February 16, 2024, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.

## Remarks:

/s/ Mihael Polymeropoulos

02/21/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.